Amy Pascoe, Harrison Birch, Natasha Smallwood
9 min
Chronic breathlessness is a distressing and highly prevalent symptom across various nonmalignant chronic respiratory diseases (CRDs), such as COPD and interstitial lung disease. Because breathlessness is often multifactorial—stemming from physical, psychological, and physiological triggers—it poses a substantial challenge to clinicians and significantly impacts patient quality of life. This review outlines a systematic, three-step management strategy designed to improve patient outcomes and alleviate the burden on healthcare systems.
The authors propose a sequential framework for addressing breathlessness:
The review critically assesses the use of medication for symptom relief. Notably, commonly prescribed pharmacological treatments like opioids and benzodiazepines lack consistent, high-quality evidence for effectiveness in routine daily use for nonmalignant CRD. These drugs also carry significant risks of adverse events. Consequently, they are not recommended as first-line therapies, except potentially in palliative care contexts under close supervision.
Because specialist respiratory services are limited, the authors argue for expanding the capacity of primary and community care. Shifting toward integrated multidisciplinary models—where respiratory specialists, physiotherapists, and palliative care teams collaborate—can improve accessibility. Furthermore, empowering patients through structured self-management programs is vital. By providing patients with education and tools to manage their symptoms, healthcare systems can reduce unnecessary hospital admissions and enhance patient autonomy.
Chronic respiratory diseases encompass diverse, nonmalignant respiratory diseases that share common symptoms, including cough, fatigue and chronic breathlessness. Chronic breathlessness imposes a significant burden on patients and is challenging for clinicians to manage effectively. Effective management of breathlessness requires a stepwise approach that involves 1) recognition and measurement of the symptom; 2) identification and optimal disease-directed management of any underlying conditions; and 3) consideration and trial of nonpharmacological management approaches. Currently, there is a dearth of safe and effective pharmacological approaches. Models of care for managing breathlessness vary broadly. While integrated specialist respiratory services are effective at improving breathlessness management, they are limited in capacity. Upskilling primary and community care can expand the reach and accessibility of breathlessness management. Ultimately, fostering self-management skills to empower people with breathlessness to better control their daily symptoms is core to improving efficiency within breathlessness care.
Alex: Measurement sounds straightforward until someone’s lung tests and lived experience disagree. Does the review address that gap?
Sam: It says symptom severity often correlates poorly with measured lung function. A brief questionnaire about how breathlessness limits activity can help patients communicate their experience. Repeating that assessment also gives clinicians a way to follow symptoms over time.
Alex: So recognise the symptom, then investigate and treat the contributors. What remains to work on when disease treatment is already optimised?
Sam: A reinforcing cycle. Breathlessness can provoke fear and panic. People may then avoid activity, become physically deconditioned, and experience further limitations. The review uses a model linking breathing, thinking and functioning to explain why symptom care needs several approaches.
Alex: That could sound like saying breathlessness is psychological. How do the authors avoid that interpretation?
Sam: They describe interacting physical and emotional processes, not an imaginary symptom. Pulmonary rehabilitation combines exercise training, education and behavioural support. The review treats it as established care, then concentrates on additional options that can help interrupt that cycle.
Alex: What is a concrete example of an additional option, and how convincing is the evidence?
Sam: Directing airflow toward the mouth and nose, often with a handheld fan. It may reduce the sensation of breathlessness, although the mechanism remains uncertain. A pooled analysis found mixed results: the average improvement wasn’t clinically meaningful, but uncertainty included a potentially meaningful benefit.
Alex: That sounds weaker than a recommendation to use fans might imply. Why include them in the toolkit?
Sam: Because cost and harm matter alongside certainty. The authors describe these approaches as inexpensive, low risk and relatively easy to teach. That supports trying them within holistic care, not promising that they reliably relieve everyone’s symptoms.
Alex: Do breathing exercises have firmer support, or is the evidence similarly tentative?
Sam: A pooled analysis included about three hundred participants testing pursed-lip breathing and breathing focused on the diaphragm, the main breathing muscle. Breathlessness-related activity limitation improved over about a month. But the review still characterises the evidence for these practical approaches as low certainty.
Alex: Oxygen is another familiar response to breathing difficulty. Does the review separate feeling breathless from having low blood oxygen?
Sam: Yes. Oxygen has established benefits for people with respiratory disease and low blood oxygen. Without low oxygen, the benefit is less clear. And the setting of measurement matters: relief during supervised exertion doesn’t necessarily mean relief during everyday life.
Alex: Is that distinction supported by actual comparisons, rather than just a concern about generalising laboratory results?
Sam: Pooled exertion trials involving about two hundred and fifty participants found reduced breathlessness with supplemental oxygen. A separate trial involving about two hundred and ten participants found no effect on breathlessness in daily life. These are different studies, not a direct comparison between settings.
Alex: And any benefit has to justify using the equipment. The review describes burdens including visible equipment, tubing-related falls and fire risks.
Sam: Which makes oxygen an individual decision, not a default response to breathlessness. Now, the same distinction between exertion and daily life helps explain the review’s reassessment of opioids.
Alex: Opioids have appeared in previous recommendations. What changed, according to these authors?
Sam: Earlier recommendations relied largely on underpowered studies, sometimes blending exercise-test outcomes with everyday breathlessness. More recent, adequately powered trials shifted the overall balance. The review reports no significant effectiveness for daily-life breathlessness in people with chronic respiratory disease and moderate to severe symptoms.
Alex: Does that conclusion extend to someone experiencing severe distress at the very end of life?
Sam: The authors explicitly preserve that distinction. Evidence at the very end of life is limited, and some subgroup analyses suggest benefit in severe breathlessness. They say opioids should remain an option in palliative care, with shared decision-making rather than routine prescribing.
Alex: Palliative care means holistic symptom relief for life-limiting illness, not only care during the final days. Does bringing that expertise into respiratory services help?
Sam: The review describes integrated breathlessness services combining respiratory, physical and psychological care, sometimes with palliative care. These services have improved breathlessness mastery: people’s sense of control over their symptoms. Patients and carers generally find them acceptable, but specialist capacity remains limited.
Alex: So the service argument cannot stop at creating more specialist clinics. What role do community care and patients themselves have?
Sam: The authors favour strengthening primary care and supported self-management. Patients learn to recognise symptoms and use personalised strategies, while clinicians guide and monitor them. A cited review found improved quality of life and fewer respiratory-related hospital admissions, though the effective programme ingredients remain unclear.
Alex: For someone deciding whether to read the full document, where is its strongest value?
Sam: Respiratory and symptom-management researchers should start with “Stepwise management of chronic breathlessness,” then “Pharmacological approaches.” Read the distinction between exertion and daily-life outcomes closely. Service researchers should turn to “Models of care,” especially supported self-management and access beyond specialist clinics.
Alex: And what should everyone else remember after the details fade?
Sam: Optimising disease treatment is not the end of breathlessness care. The symptom still deserves attention, practical support and follow-up, even when medicines offer little.
Alex: Thanks for listening.